COVID-19 vaccine from Johnson & Johnson: Swissmedic approves the third vaccine against COVID-19
Bern, 22.3.2021 - Application for authorisation submitted by Janssen-Cilag AG approved: Swissmedic has temporarily authorised the "Covid-19 vaccine Janssen" developed by the pharmaceutical corporation Johnson & Johnson for people aged 18 and over. This brings to three the number of vaccines officially authorised for distribution in Switzerland for the prevention of COVID-19. The vector vaccine based on a human adenovirus only needs to be administered as a single dose. The submitted study data show an average efficacy of 66.9 percent in the investigated age groups.